Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Phase 2

Conditions: Advanced Nsclc

Interventions: Drug: Thalidomide
Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2017-02-23

Last Posted Date: 2019-06-05

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 232

Registration Number: NCT03062800

Locations: 🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Phase 3

Conditions: Stomach Neoplasms
Chemotherapy Effect
Chemotherapeutic Toxicity

Interventions: Drug: Docetaxel
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Irinotecan
Drug: Pemetrexed
Drug: S1

First Posted Date: 2017-02-23

Last Posted Date: 2017-09-15

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 240

Registration Number: NCT03061058

Locations: 🇨🇳
Ma'anshan People's Hospital, Ma'anshan, Anhui, China
🇨🇳
Xuzhou Central Hospital, Xuzhou, Jiangsu, China
🇨🇳
Suqian People's Hospital, Suqian, Jiangsu, China

and more 5 locations

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

Phase 3

Withdrawn

Conditions: NSCLC

Interventions: Drug: AC0010
Drug: Pemetrexed
Drug: Cisplatin 75mg/m2

First Posted Date: 2017-02-20

Last Posted Date: 2019-02-04

Lead Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Registration Number: NCT03058094

Locations: 🇨🇳
Chinese General PLA Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 18 locations

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2017-02-10

Last Posted Date: 2017-02-10

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 96

Registration Number: NCT03050437

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Phase 2

Terminated

Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Squamous Cell Lung Cancer
Lung Cancer
Adenocarcinoma of the Lung

Interventions: Drug: Docetaxel
Drug: Nivolumab
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2017-02-02

Last Posted Date: 2022-07-11

Lead Sponsor: Nasser Hanna, M.D.

Target Recruit Count: 3

Registration Number: NCT03041181

Locations: 🇺🇸
St. Vincent Anderson Regional Hospital, Anderson, Indiana, United States
🇺🇸
IU Health Ball Memorial Hospital Cancer Center, Muncie, Indiana, United States
🇺🇸
Community Healthcare System, Munster, Indiana, United States

and more 6 locations

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Peritoneal Cancer
Thymus Cancer
Mesothelioma
Thymoma
Uterine Cervical Cancer
Bladder Cancer
Ovarian Cancer

Interventions: Drug: Bosutinib
Drug: Pemetrexed

First Posted Date: 2017-01-18

Last Posted Date: 2022-06-14

Lead Sponsor: Nagla Abdel Karim

Target Recruit Count: 6

Registration Number: NCT03023319

Locations: 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Cisplatin
Drug: Vinorelbine
Biological: Ipilimumab
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2016-12-20

Last Posted Date: 2023-10-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT02998528

Locations: 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Local Institution - 0151, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0006, Boston, Massachusetts, United States

and more 132 locations

Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)

Phase 2

Completed

Conditions: Lung Adenocarcinoma

Interventions: Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-12-02

Last Posted Date: 2023-07-20

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT02980991

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Phase 1

Completed

Conditions: Lung Cancer
Advanced Non-small Cell Lung Cancer
KRAS Gene Mutation

Interventions: Drug: Binimetinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-11-16

Last Posted Date: 2021-07-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT02964689

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 1 locations

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: vibostolimab
Biological: pembrolizumab/vibostolimab coformulation
Biological: pembrolizumab
Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin
Drug: etoposide

First Posted Date: 2016-11-15

Last Posted Date: 2024-08-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 470

Registration Number: NCT02964013

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy